Edwards Net Income From Continuing Ops from 2010 to 2025
| EW Stock | USD 70.91 0.28 0.39% |
Net Income From Continuing Ops | First Reported 2000-03-31 | Previous Quarter 362.1 M | Current Value 345 M | Quarterly Volatility 148 M |
Check Edwards Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edwards Lifesciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 92.8 M, Interest Expense of 11 M or Selling General Administrative of 1.9 B, as well as many indicators such as Price To Sales Ratio of 4.44, Dividend Yield of 0.0 or PTB Ratio of 4.78. Edwards financial statements analysis is a perfect complement when working with Edwards Lifesciences Valuation or Volatility modules.
Edwards | Net Income From Continuing Ops |
Latest Edwards Lifesciences' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Edwards Lifesciences Corp over the last few years. It is Edwards Lifesciences' Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edwards Lifesciences' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Edwards Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 807,703,458 | |
| Geometric Mean | 677,749,127 | |
| Coefficient Of Variation | 56.39 | |
| Mean Deviation | 368,978,458 | |
| Median | 811,100,000 | |
| Standard Deviation | 455,445,671 | |
| Sample Variance | 207430.8T | |
| Range | 1.3B | |
| R-Value | 0.86 | |
| Mean Square Error | 58960.5T | |
| R-Squared | 0.73 | |
| Significance | 0.000022 | |
| Slope | 81,997,397 | |
| Total Sum of Squares | 3111461.4T |
Edwards Net Income From Continuing Ops History
About Edwards Lifesciences Financial Statements
Edwards Lifesciences investors use historical fundamental indicators, such as Edwards Lifesciences' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edwards Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 1.4 B | 883 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Edwards Stock Analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.